A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

NCT02034552 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)
DRUG: Abiraterone acetate
DRUG: Prednisone
DRUG: Enzalutamide

Sponsor

Bayer